Differing natural killer cell, T cell and antibody profiles in antiretroviral-naive HIV-1 viraemic controllers with and without protective HLA alleles.
Autorzy:
Moyano A; Africa Health Research Institute, KwaZulu-Natal, South Africa, Durban, South Africa.; HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa. Ndlovu B; HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa. Mbele M; HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa. Naidoo K; HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa. Khan N; HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa. MannJK; HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa. Ndung'u T; Africa Health Research Institute, KwaZulu-Natal, South Africa, Durban, South Africa.; HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, School of Laboratory Medicine and Medical Sciences, University of KwaZulu-Natal, Durban, South Africa.; Division of Infection and Immunity, University College London, London, United Kingdom.; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA, United States of America.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2023 Jun 02; Vol. 18 (6), pp. e0286507. Date of Electronic Publication: 2023 Jun 02 (Print Publication: 2023).
HIV-1 subtype C Nef-mediated SERINC5 down-regulation significantly contributes to overall Nef activity.
Autorzy:
Naicker D; HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, 4001, South Africa. Sonela N; HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, 4001, South Africa.; Chantal BIYA International Reference Centre for Research on HIV/AIDS Prevention and Management (CIRCB), P.O. Box 3077, Yaoundé, Cameroon. Jin SW; Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, V5A 1S6, Canada. Mulaudzi T; HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, 4001, South Africa. Ojwach D; HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, 4001, South Africa. Reddy T; Medical Research Council, Biostatistics Unit, Durban, 4001, South Africa. Brockman MA; Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, V5A 1S6, Canada.; Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, V5A 1S6, Canada.; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, V6Z 1Y6, Canada. Brumme ZL; Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, V5A 1S6, Canada.; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, BC, V6Z 1Y6, Canada. Ndung'u T; HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, 4001, South Africa.; Africa Health Research Institute, Durban, 4001, South Africa.; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA.; Division of Infection and Immunity, University College London, London, WC1E 6BT, UK. MannJK; HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, 4001, South Africa. .
Pokaż więcej
Źródło:
Retrovirology [Retrovirology] 2023 Mar 31; Vol. 20 (1), pp. 3. Date of Electronic Publication: 2023 Mar 31.
Results of a clinician questionnaire assessing the design and feasibility of the SeCondary intention vs. grAfts for heaLing scalP wounds (SCALP) study.
Autorzy:
Hunt WTN; Dermatology Surgery Unit, Department of Dermatology, Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust, Plymouth, UK. MannJK; Department of Dermatology, University Hospitals of Derby and Burton NHS Foundation Trust, Derby, UK. Ashraf I; Department of Dermatology, Warwick Hospital, South Warwickshire University NHS Foundation Trust, Warwick, UK. Gnanappiragasam D; Department of Dermatology, University Hospitals of Leicester NHS Trust, Leicester, UK. Barlow R; Department of Dermatology, Birmingham City Hospital Dudley Road, Birmingham B18 7QH, UK. DeGiovanni C; Department of Dermatology, Brighton General Hospital, University Hospitals Sussex NHS Foundation Trust, Brighton, UK. Abbott R; Welsh Institute of Dermatology, Cardiff and Vale University Local Health Board, Cardiff, UK. Wernham AGH; Department of Dermatology, Walsall Manor Hospital, Walsall Healthcare NHS Trust, Walsall, UK.
A review of Mohs micrographic surgery for skin cancer. Part 1: Melanoma and rare skin cancers.
Autorzy:
Charalambides M; Department of Dermatology, City Hospital, Sandwell and West Birmingham NHS Trust, Birmingham, UK. Yannoulias B; Department of Dermatology, New Cross Hospital, The Royal Wolverhampton NHS Trust, Wolverhampton, UK. Malik N; Watford General Hospital, West Hertfordshire Hospitals NHS Trust, Watford, UK. MannJK; Department of Dermatology, Royal Derby Hospital, University Hospitals of Derby and Burton NHS Foundation Trust, Derby, UK. Celebi P; Department of Dermatology, Royal Derby Hospital, University Hospitals of Derby and Burton NHS Foundation Trust, Derby, UK. Veitch D; Department of Dermatology, Leicester Royal Infirmary, University Hospitals of Leicester NHS Trust, Leicester, UK. Wernham A; Department of Dermatology, Manor Hospital, Walsall Healthcare NHS Trust, Walsall, UK.
Subtype-specific differences in Gag-protease replication capacity of HIV-1 isolates from East and West Africa.
Autorzy:
Farinre O; HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa. Gounder K; HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa.; Africa Health Research Institute, Durban, 4001, South Africa. Reddy T; Biostatistics Research Unit, South African Medical Research Council, Durban, South Africa. Tongo M; Centre of Research for Emerging and Re-Emerging Diseases (CREMER), Yaoundé, Cameroon. Hare J; International AIDS Vaccine Initiative (IAVI) Human Immunology Laboratory (HIL), Imperial College, London, UK.; IAVI Global Headquarters, 125 Broad Street, 9th Floor,, New York, NY, USA. Chaplin B; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, USA. Gilmour J; International AIDS Vaccine Initiative (IAVI) Human Immunology Laboratory (HIL), Imperial College, London, UK.; IAVI Global Headquarters, 125 Broad Street, 9th Floor,, New York, NY, USA. Kanki P; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA, USA. MannJK; HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa. Ndung'u T; HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa. .; Africa Health Research Institute, Durban, 4001, South Africa. .; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA. .; Max Planck Institute for Infection Biology, Berlin, Germany. .; Division of Infection and Immunity, University College London, London, UK. .
Pokaż więcej
Źródło:
Retrovirology [Retrovirology] 2021 May 05; Vol. 18 (1), pp. 11. Date of Electronic Publication: 2021 May 05.
Variation in HIV-1 Nef function within and among viral subtypes reveals genetically separable antagonism of SERINC3 and SERINC5.
Autorzy:
Jin SW; Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada. Mwimanzi FM; Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada. MannJK; HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa. Bwana MB; Faculty of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda. Lee GQ; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada. Brumme CJ; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada.; Department of Medicine, University of British Columbia, Vancouver, Canada. Hunt PW; School of Medicine, University of California, San Francisco, United States of America. Martin JN; School of Medicine, University of California, San Francisco, United States of America. Bangsberg DR; School of Public Health, Oregon Health Science University, Portland, United States of America. Ndung'u T; HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa.; Africa Health Research Institute, Durban, South Africa.; Ragon Institute of MGH, MIT, and Harvard University, Cambridge, United States of America.; Max Planck Institute for Infection Biology, Berlin, Germany.; Division of Infection and Immunity, University College London, London, United Kingdom. Brumme ZL; Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada.; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada. Brockman MA; Faculty of Health Sciences, Simon Fraser University, Burnaby, Canada.; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, Canada.; Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, Canada.
Pokaż więcej
Źródło:
PLoS pathogens [PLoS Pathog] 2020 Sep 14; Vol. 16 (9), pp. e1008813. Date of Electronic Publication: 2020 Sep 14 (Print Publication: 2020).
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Association between the cytokine storm, immune cell dynamics, and viral replicative capacity in hyperacute HIV infection.
Autorzy:
Muema DM; Africa Health Research Institute, Durban, South Africa.; HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa.; KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya. Akilimali NA; Africa Health Research Institute, Durban, South Africa. Ndumnego OC; Africa Health Research Institute, Durban, South Africa. Rasehlo SS; Africa Health Research Institute, Durban, South Africa. Durgiah R; Africa Health Research Institute, Durban, South Africa. Ojwach DBA; HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa. Ismail N; HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa. Dong M; HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa. Moodley A; HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa. Dong KL; HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa.; Ragon Institute of MGH, MIT and Harvard University, Cambridge, MA, USA. Ndhlovu ZM; Africa Health Research Institute, Durban, South Africa.; HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa.; Ragon Institute of MGH, MIT and Harvard University, Cambridge, MA, USA. Mabuka JM; Africa Health Research Institute, Durban, South Africa. Walker BD; HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa.; Ragon Institute of MGH, MIT and Harvard University, Cambridge, MA, USA. MannJK; HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa. Ndung'u T; Africa Health Research Institute, Durban, South Africa. .; HIV Pathogenesis Programme, The Doris Duke Medical Research Institute, University of KwaZulu-Natal, Durban, South Africa. .; Ragon Institute of MGH, MIT and Harvard University, Cambridge, MA, USA. .; Max Planck Institute for Infection Biology, Berlin, Germany. .; Division of Infection and Immunity, University College London, London, UK. .
Pokaż więcej
Źródło:
BMC medicine [BMC Med] 2020 Mar 25; Vol. 18 (1), pp. 81. Date of Electronic Publication: 2020 Mar 25.
Genetic determinants of Nef-mediated CD4 and HLA class I down-regulation differences between HIV-1 subtypes B and C.
Autorzy:
MannJK; HIV Pathogenesis Programme, University of KwaZulu-Natal, 719 Umbilo Road, Durban, 4013, South Africa. .; KwaZulu-Natal Research Institute for Tuberculosis and HIV, University of KwaZulu-Natal, Durban, 4001, South Africa. . Omarjee S; HIV Pathogenesis Programme, University of KwaZulu-Natal, 719 Umbilo Road, Durban, 4013, South Africa. .; KwaZulu-Natal Research Institute for Tuberculosis and HIV, University of KwaZulu-Natal, Durban, 4001, South Africa. . Khumalo P; HIV Pathogenesis Programme, University of KwaZulu-Natal, 719 Umbilo Road, Durban, 4013, South Africa. .; KwaZulu-Natal Research Institute for Tuberculosis and HIV, University of KwaZulu-Natal, Durban, 4001, South Africa. . Ndung'u T; HIV Pathogenesis Programme, University of KwaZulu-Natal, 719 Umbilo Road, Durban, 4013, South Africa. .; KwaZulu-Natal Research Institute for Tuberculosis and HIV, University of KwaZulu-Natal, Durban, 4001, South Africa. .; Ragon Institute of MGH, MIT and Harvard University, Cambridge, MA, 02139, USA. .; Max Planck Institute for Infection Biology, Chariteplatz, D-10117, Berlin, Germany. .
Pokaż więcej
Źródło:
Virology journal [Virol J] 2015 Nov 25; Vol. 12, pp. 200. Date of Electronic Publication: 2015 Nov 25.
Selection of an HLA-C*03:04-Restricted HIV-1 p24 Gag Sequence Variant Is Associated with Viral Escape from KIR2DL3+ Natural Killer Cells: Data from an Observational Cohort in South Africa.
Autorzy:
Hölzemer A; Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, United States of America.; Heinrich-Pette-Institut, Leibniz Institute for Experimental Virology, Hamburg, Germany.; First Department of Internal Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. Thobakgale CF; Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, United States of America.; HIV Pathogenesis Programme, Doris Duke Medical Research Institute, KwaZulu-Natal Research Institute for Tuberculosis and HIV, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa. Jimenez Cruz CA; Computational Biology Center, IBM Thomas J. Watson Research Center, Yorktown Heights, New York, United States of America. Garcia-Beltran WF; Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, United States of America. Carlson JM; Microsoft Research, Los Angeles, California, United States of America. van Teijlingen NH; Experimental Immunology, Academic Medical Center, Amsterdam, The Netherlands. MannJK; HIV Pathogenesis Programme, Doris Duke Medical Research Institute, KwaZulu-Natal Research Institute for Tuberculosis and HIV, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa. Jaggernath M; HIV Pathogenesis Programme, Doris Duke Medical Research Institute, KwaZulu-Natal Research Institute for Tuberculosis and HIV, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa. Kang SG; Computational Biology Center, IBM Thomas J. Watson Research Center, Yorktown Heights, New York, United States of America. Körner C; Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, United States of America.; Heinrich-Pette-Institut, Leibniz Institute for Experimental Virology, Hamburg, Germany. Chung AW; Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, United States of America. Schafer JL; Department of Microbiology and Immunobiology, Harvard Medical School, Boston, Massachusetts, United States of America.; Division of Microbiology, New England Primate Research Center, Southborough, Massachusetts, United States of America. Evans DT; Department of Microbiology and Immunobiology, Harvard Medical School, Boston, Massachusetts, United States of America.; Division of Microbiology, New England Primate Research Center, Southborough, Massachusetts, United States of America.; Department of Pathology and Laboratory Medicine, University of Wisconsin, Madison, Madison, Wisconsin, United States of America. Alter G; Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, United States of America. Walker BD; Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, United States of America. Goulder PJ; HIV Pathogenesis Programme, Doris Duke Medical Research Institute, KwaZulu-Natal Research Institute for Tuberculosis and HIV, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.; Department of Paediatrics, University of Oxford, Oxford, United Kingdom. Carrington M; Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, United States of America.; Cancer and Inflammation Program, Laboratory of Experimental Immunology, Leidos Biomedical Research, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America. Hartmann P; First Department of Internal Medicine, Division of Infectious Diseases, University of Cologne, Cologne, Germany.; Institute for Medical Microbiology, Immunology and Hygiene, University of Cologne, Cologne, Germany. Pertel T; Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America. Zhou R; Computational Biology Center, IBM Thomas J. Watson Research Center, Yorktown Heights, New York, United States of America. Ndung'u T; Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, United States of America.; HIV Pathogenesis Programme, Doris Duke Medical Research Institute, KwaZulu-Natal Research Institute for Tuberculosis and HIV, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa.; Max Planck Institute for Infection Biology, Berlin, Germany.; KwaZulu-Natal Research Institute for Tuberculosis and HIV, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa. Altfeld M; Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, United States of America.; Heinrich-Pette-Institut, Leibniz Institute for Experimental Virology, Hamburg, Germany.
Pokaż więcej
Źródło:
PLoS medicine [PLoS Med] 2015 Nov 17; Vol. 12 (11), pp. e1001900; discussion e1001900. Date of Electronic Publication: 2015 Nov 17 (Print Publication: 2015).
Typ publikacji:
Journal Article; Observational Study; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
High frequency of transmitted HIV-1 Gag HLA class I-driven immune escape variants but minimal immune selection over the first year of clade C infection.
Autorzy:
Gounder K; HIV Pathogenesis Programme, Doris Duke Medical Research Institute, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, 719 Umbilo Road, Durban, South Africa; KwaZulu-Natal Research Institute for Tuberculosis and HIV, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, 719 Umbilo Road, Durban, South Africa. Padayachi N; HIV Pathogenesis Programme, Doris Duke Medical Research Institute, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, 719 Umbilo Road, Durban, South Africa; KwaZulu-Natal Research Institute for Tuberculosis and HIV, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, 719 Umbilo Road, Durban, South Africa. MannJK; HIV Pathogenesis Programme, Doris Duke Medical Research Institute, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, 719 Umbilo Road, Durban, South Africa; KwaZulu-Natal Research Institute for Tuberculosis and HIV, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, 719 Umbilo Road, Durban, South Africa. Radebe M; HIV Pathogenesis Programme, Doris Duke Medical Research Institute, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, 719 Umbilo Road, Durban, South Africa; KwaZulu-Natal Research Institute for Tuberculosis and HIV, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, 719 Umbilo Road, Durban, South Africa. Mokgoro M; HIV Pathogenesis Programme, Doris Duke Medical Research Institute, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, 719 Umbilo Road, Durban, South Africa; KwaZulu-Natal Research Institute for Tuberculosis and HIV, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, 719 Umbilo Road, Durban, South Africa. van der Stok M; HIV Pathogenesis Programme, Doris Duke Medical Research Institute, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, 719 Umbilo Road, Durban, South Africa; KwaZulu-Natal Research Institute for Tuberculosis and HIV, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, 719 Umbilo Road, Durban, South Africa. Mkhize L; HIV Pathogenesis Programme, Doris Duke Medical Research Institute, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, 719 Umbilo Road, Durban, South Africa; KwaZulu-Natal Research Institute for Tuberculosis and HIV, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, 719 Umbilo Road, Durban, South Africa. Mncube Z; HIV Pathogenesis Programme, Doris Duke Medical Research Institute, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, 719 Umbilo Road, Durban, South Africa; KwaZulu-Natal Research Institute for Tuberculosis and HIV, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, 719 Umbilo Road, Durban, South Africa. Jaggernath M; HIV Pathogenesis Programme, Doris Duke Medical Research Institute, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, 719 Umbilo Road, Durban, South Africa; KwaZulu-Natal Research Institute for Tuberculosis and HIV, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, 719 Umbilo Road, Durban, South Africa. Reddy T; Biostatistics Unit, Medical Research Council, 491 Peter Mokaba Road, Overport, Durban, South Africa. Walker BD; HIV Pathogenesis Programme, Doris Duke Medical Research Institute, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, 719 Umbilo Road, Durban, South Africa; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, 400 Technology Square, Cambridge, Boston, Massachusetts, United States of America; Howard Hughes Medical Institute, 4000 Jones Bridge Road, Chevy Chase, MD, United States of America. Ndung'u T; HIV Pathogenesis Programme, Doris Duke Medical Research Institute, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, 719 Umbilo Road, Durban, South Africa; KwaZulu-Natal Research Institute for Tuberculosis and HIV, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, 719 Umbilo Road, Durban, South Africa; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, 400 Technology Square, Cambridge, Boston, Massachusetts, United States of America; Max Planck Institute for Infection Biology, Charitestraße 1, Berlin, Germany.
Pokaż więcej
Źródło:
PloS one [PLoS One] 2015 Mar 17; Vol. 10 (3), pp. e0119886. Date of Electronic Publication: 2015 Mar 17 (Print Publication: 2015).
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
The fitness landscape of HIV-1 gag: advanced modeling approaches and validation of model predictions by in vitro testing.
Autorzy:
MannJK; HIV Pathogenesis Programme, Doris Duke Medical Research Institute, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa; KwaZulu-Natal Research Institute for Tuberculosis and HIV (K-RITH), Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa. Barton JP; Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Boston, Massachusetts, United States of America. Ferguson AL; Department of Materials Science and Engineering, University of Illinois at Urbana-Champaign, Urbana, Illinois, United States of America. Omarjee S; HIV Pathogenesis Programme, Doris Duke Medical Research Institute, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa; KwaZulu-Natal Research Institute for Tuberculosis and HIV (K-RITH), Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa. Walker BD; HIV Pathogenesis Programme, Doris Duke Medical Research Institute, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Boston, Massachusetts, United States of America; Howard Hughes Medical Institute, Chevy Chase, Maryland, United States of America. Chakraborty A; Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts, United States of America; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Boston, Massachusetts, United States of America; Departments of Chemistry and Physics, Massachusetts Institute of Technology, Boston, Massachusetts, United States of America. Ndung'u T; HIV Pathogenesis Programme, Doris Duke Medical Research Institute, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa; KwaZulu-Natal Research Institute for Tuberculosis and HIV (K-RITH), Nelson R Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa; Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Boston, Massachusetts, United States of America; Max Planck Institute for Infection Biology, Berlin, Germany.
Pokaż więcej
Źródło:
PLoS computational biology [PLoS Comput Biol] 2014 Aug 07; Vol. 10 (8), pp. e1003776. Date of Electronic Publication: 2014 Aug 07 (Print Publication: 2014).
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
No evidence for selection of HIV-1 with enhanced gag-protease or Nef function among breakthrough infections in the CAPRISA 004 tenofovir microbicide trial.
Autorzy:
Chopera DR; HIV Pathogenesis Programme, Doris Duke Medical Research Institute, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa ; KwaZulu-Natal Research Institute for Tuberculosis and HIV, Nelson R. Mandela School of Medicine, University of KwaZulu-Natal, Durban, South Africa ; Institute of Infectious Disease and Molecular Medicine, and the Division of Medical Virology, University of Cape Town and National Health Laboratory Services, Cape Town, South Africa ; Faculty of Health Sciences, Simon Fraser University, Burnaby, British Columbia, Canada ; British Columbia Centre for Excellence in HIV/AIDS, Vancouver, British Columbia, Canada. MannJK Mwimanzi P Omarjee S Kuang XT Ndabambi N Goodier S Martin E Naranbhai V Karim SA Karim QA Brumme ZL Ndung'u T Williamson C Brockman MA
Hin-mediated DNA knotting and recombining promote replicon dysfunction and mutation.
Autorzy:
Deibler RW; Interdepartmental Program in Cell and Molecular Biology, Baylor College of Medicine, Houston, Texas 77030-3411, USA. richard_ MannJK Sumners de WL Zechiedrich L
Pokaż więcej
Źródło:
BMC molecular biology [BMC Mol Biol] 2007 May 25; Vol. 8, pp. 44. Date of Electronic Publication: 2007 May 25.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies